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Use of antiretroviral therapy and risk of end-stage
liver disease and hepatocellular carcinoma in
HIV-positive persons
Lene Ryoma, Jens Dilling Lundgrena, Ste´phane De Witb,
Helen Kovaric, Peter Reissd, Matthew Lawe, Wafa El-Sadrf,
Antonella D’Arminio Monforteg, Amanda Mocrofth, Colette Smithh,
Eric Fontasi, Francois Dabisj,k, Andrew Phillipsh, Caroline Sabinh,
for the D:A:D Study Group
Objectives: Although several antiretroviral drugs, including the d-drugs stavudine
(d4T) and didanosine (ddI), may cause biomarker-defined hepatotoxicity, their associ-
ation with clinically defined end-stage liver disease (ESLD) and hepatocellular carci-
noma (HCC) remains unknown.
Design: Prospective cohort study.
Methods: Data collection on adverse events of anti-HIV drugs study (D:A:D) partici-
pants were followed until the first of ESLD (variceal bleeding, hepatic encephalopathy,
hepatorenal syndrome or liver transplantation), HCC (histology or a-fetoprotein along
with imaging), death, 6 months after last visit or 1 February 2014. Associations between
ESLD/HCC and cumulative use of individual antiretrovirals were investigated using
Poisson regression adjusting for potential confounders.
Results: During a median follow-up of 8.4 years, 319 ESLD/HCC cases occurred
[incidence 1.01/1000 person-years (95% confidence interval 0.90–1.12)] with a 1-year
mortality rate of 62.6%. After adjustment, cumulative (per 5 years) exposure to d4T
[relative rate 1.46 (95% confidence interval 1.20–1.77)], ddI [1.32 (1.07–1.63)], teno-
fovir [TDF, 1.46 (1.11–1.93)] and (fos)amprenavir [APV; 1.47 (1.01–2.15)] was associ-
ated with increased ESLD/HCC rates. Longer exposure to emtricitabine [0.51 (0.32–
0.83)] and nevirapine [0.76 (0.58–0.98)] were associated with lower ESLD/HCC rates.
The ddI/d4T-associated increased ESLD/HCC rate only started to decline 6 years after
cessation.
Conclusion: Cumulative use of d4T, ddI, TDF and APV were independently associated
with increased ESLD/HCC rates, and intensified monitoring of liver function should
hence be considered among all individuals exposed for longer time periods. The use of
d-drugs should furthermore be avoided, where there are alternatives available, and
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focus should be put on those with longer-term d-drugs exposure who remain at
increased ESLD/HCC risk. The unexpected, and viral hepatitis-independent, TDF
association calls for further investigations.
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Introduction
The majority of the antiretroviral drug classes used for the
treatment of HIV have an intrinsic potential to cause
hepatotoxicity, which may be induced through various
mechanisms [1–4]. Previous studies have estimated that
up to 30% of all HIV-positive persons will experience
some form of hepatotoxicity associated with antiretroviral
treatment (ART) [1–3]. Studies that have investigated
adverse ART-liver effects have commonly been based on
changes in liver-related biomarkers such as transaminases
[3,5–9], fibrosis markers (e.g., hyaluronic acid) [10],
imaging modalities or biopsy findings [11–17]. Further-
more, most studies have been of a relatively modest size or
of a cross-sectional nature, making assessments of the time
course between exposure and outcomes difficult [13–19].
Studies have also been primarily conducted among
individuals who are coinfected with HIV and viral
hepatitis, in whom the incidence of adverse hepatic
impairment is elevated compared with HIV mono-
infected individuals [5,14,18,20,21]. Indeed, a previous
data collection on adverse events of anti-HIV drugs
(D:A:D) study analysis in participant without viral
hepatitis found that deaths related to liver failure are
rare in HIV-positive individuals without viral hepatitis B
(HBV) or C (HCV) [20].
The adverse effects of ART on development of liver
impairment have been debated for years [20,22–25]. The
diverse study outcomes are, however, not surprising as
these will naturally depend on the individual antiretroviral
investigated. ART is known to have an overall beneficial
effect on liver-related outcomes, largely because of
attenuating liver disease progression in viral hepatitis
coinfected individuals by improvements in immune
function [22,24], and the direct antiviral effect on
HBV by certain individual antiretrovirals such as
tenofovir (TDF), lamivudine (3TC) and emtricitabine
(FTC). Conversely, other antiretrovirals, such as tipra-
navir (TPV), have a known direct hepatotoxic effect [4].
Furthermore, an excess risk of liver-related death with
cumulative ART use has been observed after accounting
for improvements in the CD4þ cell count [24,26].
Among the individual antiretrovirals, dideoxynucleoside
analogues or ‘d-drugs’ and, in particular, didanosine (ddI)
and stavudine (d4T) have commonly been associated with
alterations in liver function and severe steatosis/fibrosis
development [11,13,16,17,27–31]. Moreover, ddI use
has been linked with development of noncirrhotic portal
hypertension [32,33]. Use of d-drugs is now rare in most
high-income countries because of their serious adverse
effects including neuropathy and lipodystrophy [4].
D-drug use was, however, common in the past, and
previous exposure may also impact on subsequent liver
function [34]. In 2010, the WHO launched an initiative
aiming to reduce the use of d4T. However, many
individuals in resource-limited settings continue to use
d-drugs because of their widespread availability and low
cost; as such, an estimated 1.1 million individuals still
initiated a d4T-based first-line antiretroviral regimen in
2011 [35,36].
Of the nonnucleoside reverse transcriptase inhibitors
(NNRTIs), in particular, nevirapine (NVP) has been
linked to hepatotoxicity as part of a systemic hypersensi-
tivity reaction [1,26,37–39]. Compared with the
suspected liver steatosis/fibrosis effect of d-drugs and
other nucleoside reverse transcriptase inhibitors (NRTIs),
the NNRTI class effect on the liver is of a hepatitis-like
nature [1,4,26,37–39].
Among the protease inhibitors (PIs), in particular,
atazanavir (ATV) may cause hyperbilirubinemia and
cholecystolithiasis, whereas TPV-related hepatitis is
expected in 10% of recipients [4,40,41]. Coinfection
with viral hepatitis has been associated with increased
plasma levels of PIs, but the clinical impact of coinfection
on antiretroviral-related hepatotoxicity is unknown
[42].
Although most antiretroviral-related adverse liver effects
are reported to be acute, mild and asymptomatic [3],
prospective investigations of long-term antiretroviral use
and clinical manifestations of end-stage liver disease
(ESLD) and hepatocellular carcinoma (HCC) have not, as
yet, been conducted in a large heterogeneous cohort
setting. This analysis aimed to describe incidence rates,
predictors and survival after ESLD/HCC with focus on
the potential association with cumulative use of individual
antiretrovirals, and, in particular, d-drugs, because of their
high susceptibility to induce fibrosis.
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Methods
Study population
The D:A:D study is a prospective cohort collaboration
established in 1999 which follows more than 49 000 HIV-
1-positive persons in Europe, the United States and
Australia; details have been previously published [17].
Data on clinical events including ESLD, cancers,
myocardial infarction, stroke, invasive cardiovascular
procedures and death are collected in real time during
routine clinical care. Events are validated centrally and
monitored regularly. In addition, information on
demographic factors, ART, viral hepatitis, laboratory
test results, cardiovascular risk factors and AIDS events is
electronically collected at enrolment and every 6 months.
Endpoint definition
From 1 February 2004 onwards, systematic collection of
ESLD and cancer events (including HCC) was initiated in
D:A:D. A designated ESLD event form was developed to
collect detailed information on the clinical symptoms
defining ESLD: bleeding from endoscopically verified
gastric or oesophageal varices; stages III–IV hepatic
encephalopathy; hepatorenal syndrome or liver trans-
plantation (more information at www.chip.dk). In
addition, pathology reports and transient elastographies
results are collected. Information on HCC, including
histology findings or the combination of elevated a-
fetoprotein and HCC-specific imaging findings, is
collected on a designated cancer form. Where a diagnosis
of ESLD/HCC was reported only on a fatal case
reporting form (Coding Causes of deaths in HIV, CoDe,
more information at www.chip.dk) [43], the death was
only considered to be an ESLD or HCC event if
information was provided on the clinical symptoms and
histology/imaging findings.
Statistical methods
D:A:D participants were followed from the date of
enrolment in the study or 1 February 2004, if this was later
(baseline), until the first of an ESLD/HCC event, death, 6
months after last visit or 1 February 2014. Only the first
ESLD or HCC event reported for each individual during
prospective follow-up was included in the analysis.
Incidence rates were calculated per 1000 person-years of
follow-up (PYFU). Kaplan–Meier estimation was used
to describe the risk of mortality following a diagnosis of
ESLD/HCC. Poisson regression models were used to
quantify the relationship between ESLD/HCC and
cumulative antiretroviral use. Potential confounders
considered for adjusted models were calendar year
(categorized as before 2008, 2008/2009 and after
2009), demographic variables [sex, age (<35 or >35
years)], ethnicity (white vs. other), participating cohort,
smoking status (current, previous, never, unknown),
HIV-related factors (route of HIV acquisition (IDU vs.
other), previous AIDS diagnosis and HBV and HCV
coinfection status (negative, positive, unknown), with
variables retained in multivariable models if they were
significantly associated (P< 0.05) with the outcome in
univariate models.
Subsequent models also considered adjustment for the
latest viral load (fitted categorically) and CD4þ cell count,
both as time-updated covariates; these covariates were
purposely not included in our primary analyses of
antiretroviral associations, as they may lie on the causal
pathway between antiretroviral exposure and ESLD/
HCC.
Antiretroviral exposure was fitted cumulatively (per
5 years) as it was hypothesized that the risk of any
adverse liver events would increase with longer exposure
[44]. All antiretroviral exposures were considered,
regardless of when they accrued – thus, individuals
may already have accrued several years of exposure to
some of the antiretrovirals prior to baseline; exposure
then continued to accrue after baseline if the individuals
continued to receive the drugs (or restarted them at a later
point in time).
An investigation of the association between time since
d-drug discontinuation and ESLD/HCC rates was
conducted adjusting for cumulative exposure to each
drug and other potential confounders. This allowed us to
assess the potential for any increased risk of ESLD/HCC
to be reversed after cessation of the drug.
All statistical analyses were carried out using SAS version
9.3 (Statistical Analysis Software, Cary, North Carolina,
USA).
Results
Characteristics
A total of 45 544 individuals were followed in D:A:D
since 1 February 2004 and were included in the analysis;
these individuals were predominantly white (49.6%), men
(73.5%) and had acquired HIV through sex between men,
MSM (44.5%) (Table 1). The median age was 40
[interquartile range (IQR) 34–46] years at baseline and
the median CD4þ cell count was 434 (IQR 282–621)
cells/ml. During a median follow-up of 8.4 (IQR 5.5–
12.6) years, a total of 319 ESLD/HCC events occurred
(incidence rate 1.01/1000 PYFU, 95% confidence
interval 0.90–1.12) of which 209 were ESLD and 110
HCC events. Overall, 157 (49.2%) of the ESLD/HCC
events were identified through an ESLD form, 88 (27.6%)
through a cancer form and the remaining 74 (23.2%)
through a death form. The most common clinical
manifestation of ESLD was hepatic encephalopathy
grades III–IV (43.3%), followed by endoscopically
verified variceal bleeding (27.4%), hepatorenal syndrome
(14.6%) and liver transplantation (5.1%), whereas 9.6%
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had more than one manifestation at the same event date.
The median age of individuals experiencing ESLD/HCC
(at the time of the event) was 47 (IQR 42–52) years, the
most common mode of HIV acquisition was IDU
(53.6%), the median CD4þ cell count was 266 (IQR
153–448) cells/ml and 72.4% were confirmed HCV
positive and 19.8% with active HBV co-infection
(Table 1). As 82.8% of all events occurred in individuals
coinfected with viral hepatitis, the ESLD/HCC incidence
rate was low in individuals without HCVor HBVevidence
[0.12/1000 PYFU (95% confidence interval 0.07-0.16)]
(Table 2). Although the ESLD/HCC incidence rate was
similar for individuals with HIV/HCV and HIV/HBV
coinfection, the number of individuals with HIV/HCV/
HBV was limited (data not shown).
Prognosis
The 319 individuals with ESLD/HCC were followed for
a median of 0.23 (IQR 0.01–1.88) years after diagnosis,
over which time 241 (75.6%) died. The median survival
after an ESLD/HCC diagnosis was 0.27 years, whereas
the 1-year mortality rate (Kaplan–Meier estimate) was
62.6%. After exclusion of 52 individuals diagnosed with
ESLD/HCC at time of death, the median survival after an
1734 AIDS 2016, Vol 30 No 11
Table 1. Characteristics of persons included in analysis at baseline and at the time of end-stage liver disease/hepatocellular carcinoma (ESLD/
HCC).
All eligible participants at baseline At the time of an ESLD/HCC event
Number of participants 45 544 (100.0) 319 (100.0)
Sex Men 33465 (73.5) 254 (79.6)
Women 12079 (26.5) 65 (20.4)
Age (years) Median (IQR) 40 (34–46) 47 (42–52)
Mode of acquisition MSM 20284 (44.5) 64 (20.1)
IDU 6396 (14.0) 171 (53.6)
Heterosexual 15 316 (33.6) 67 (21.0)
Other/unknown 3548 (7.8) 17 (5.3)
Ethnicity White 22 609 (49.6) 180 (56.4)
Black African 4263 (9.4) 12 (3.8)
Other 1265 (2.8) 1 (0.3)
Unknown 17407 (38.2) 126 (39.5)
CD4þ cell count (cells/ml) Median (IQR) 434 (282–621) 266 (153–448)
HIV RNA (log10 copies/ml) Median (IQR) 2.3 (1.7–4.3) 1.7 (1.7–2.6)
HCV statusa Negative 29002 (63.7) 71 (22.3)
Positive 8259 (18.1) 231 (72.4)
Unknown 8283 (18.2) 17 (5.3)
HBV statusb Negative/Not active 36711 (80.6%) 238 (74.6%)
Positive active 2074 (4.6) 63 (19.8)
Unknown 6759 (14.8) 18 (5.6)
Smoking status Current smoker 17 443 (38.7) 180 (56.4)
Ex-smoker 7682 (17.0) 84 (26.3)
Never smoker 11 909 (26.4) 43 (13.5)
Not known 8089 (17.9) 12 (3.8)
Previous AIDS 10846 (23.8) 155 (48.6)
aHCV status (negative: seronegative, or seropositive but HCV-RNA negative; positive: seropositive and HCV-RNA positive or HCV-RNA unknown
or not tested).
bHBV status [positive: active infection (HBs antigen, HBe antigen, or HBV-DNA positive).
Table 2. Incidence of end-stage liver disease/hepatocellular carcinoma (per 1000 person-years of follow-up) stratified by viral hepatitis status.
Factor No. of events PYFU Rate 95% CI
Overall 319 315368 1.01 0.90–1.12
HCV statusa Negative 72 229434 0.31 0.24–0.39
Positive 229 63786 3.59 3.13–4.06
Unknown 18 22148 0.81 0.48–1.28
HBV statusb Negative/Not active 240 284917 0.84 0.74-0.95
Positive active 59 12907 4.57 3.40–5.74
Unknown 20 17545 1.14 0.64–1.64
CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.
aHCV status (negative: seronegative, or seropositive but HCV-RNA negative; positive: seropositive and HCV-RNA positive or HCV-RNA unknown
or not tested).
bHBV status positive: active infection (HBs antigen, HBe antigen, or HBV-DNA positive).
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ESLD/HCC event was 0.66 years and the 1-year
mortality rate was 55.0%.
Associations between antiretroviral exposure
and end-stage liver disease and hepatocellular
carcinoma
Associations between individual antiretrovirals and
ESLD/HCC were initially explored without adjustment
for calendar year, demographics, HIV-related factors and
viral hepatitis status (but with adjustment for other
antiretrovirals in the regimen) (Fig. 1).
Among the NRTIs a linear and similar cumulative
effect of ddI and d4T was observed [d4T 1.80/5 years
(1.42–2.27) and ddI 1.55/5 years (1.25–1.92)]. Increased
exposure to 3TC [1.31/5 years (1.07–1.60)] and TDF
[1.55/5 years (1.17–2.04)] were unexpectedly also
associated with increased rates of ESLD/HCC. In
contrast, a reduced rate of ESLD/HCC was seen in
individuals with longer exposure to FTC [0.54/5 years
(0.34–0.86)]. After adjustment for potential confounders,
significant associations remained with cumulative use of
d4T [1.46/5 years (1.20–1.77)], ddI [1.32/5 years
(1.07–1.63)], TDF [1.46/5 years (1.11–1.93)] and
FTC [0.51/5 years (0.32–0.83)], whereas the association
with 3TC no longer remained significant (Fig. 1).
Among the NNRTIs, use of NVP was surprisingly
associated with a reduced rate of ESLD/HCC in both
unadjusted [0.56/5 years (0.43–0.74)] and adjusted
[0.76/5 years (0.58–0.98)] analyses.
(Fos)amprenavir (APV) was the only PI associated with
ESLD/HCC in unadjusted models [1.82/5 years (1.16–
2.85)] and this association remained significant in the fully
adjusted multivariate model [1.47/5 years (1.01–2.15)].
A sensitivity analysis stratified according to viral hepatitis
status reached consistent associations for all antiretrovirals,
including TDF, although the number of events was low in
those without evidence of HBV/HCV (data not shown).
The associations with ddI and d4Twere explored in more
detail, as determined a priori because of the potential
long-term effects on liver function after ceased use. When
exposure to ddI was considered without any d4T
exposure, the association between ddI and ESLD/
HCC was slightly reduced [1.28/5 years (0.98–1.66)] as
was d4T exposure when used without ddI [1.43/5 years
(1.16–1.77)]. When used concomitantly, the associa-
tion with ESLD/HCC was strengthened [2.03/5 years
(1.44–2.85)], however, only to the extent that would be
expected on the basis of combining the effects of each
drug when used separately, as there was no evidence of
synergy between the two drugs in this model. There was
no strong evidence to indicate that the associations
between the two d-drugs and ESLD/HCC differed
between individuals with and without viral hepatitis
coinfection (P¼ 0.50 for interaction between d4T and
any hepatitis, P¼ 0.09 for ddI and any hepatitis), although
because of the small number of events in those without
coinfection, the power to detect a significant interaction
was extremely low.
Of the 18 676 persons on d4Tor ddI, 91.4% stopped their
use at least once during follow-up, with only 18.4% of the
PYFU in those exposed to d-drugs being current users.
Those having previously stopped d-drugs had higher
ESLD/HCC rates than those currently on d-drugs, an
effect that only started to wane slightly after more than
6 years after cessation (Table 3).
Discussion
This is the first large, prospective and long-term analysis
to investigate incidence, outcomes and risk factors for
clinically defined liver failure and cancer in HIV-positive
persons with focus on the contribution of individual
antiretrovirals.
We observed a relatively low overall incidence rate of
ESLD/HCC in this large heterogeneous cohort of both
HIV monoinfected and viral hepatitis coinfected persons.
In comparison, a recent retrospective analysis from the
Veterans Affairs cohort found that among antiretroviral-
treated HIV/HCV coinfected persons, 7.4% experienced
hepatic decompensation at 10 years [45]. This higher rate
may, however, be explained by the conservative ESLD/
HCC criteria in D:A:D, and by the inclusion of ascites in
the definition of hepatic decompensation, which was not
originally included in the D:A:D definition as it may also
be seen in other noncirrhotic liver disease-related
conditions [46].
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0.5 1
APV
NVP
FTC
TDF
ddl
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ESLD/HCC incidence rate ratio (95% CI) per 5 years exposure
2
Adjusted
Fig. 1. Association between cumulative (per 5 year) antire-
troviral exposure and end-stage liver disease/hepatocellular
carcinoma (ESLD/HCC). APV, (fos)amprenavir; d4T, stavu-
dine; ddI, didanosine; FTC, emtricitabine; NVP, nevirapine;
TDF, tenofovir.
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The prognosis following ESLD/HCC was poor with a
median survival of only 0.27 years. This observation calls
for an increased awareness of ESLD/HCC risk factors and
management. The recent introduction of effective direct-
acting agents (DAAs) for treatment of HCV will likely
change the ESLD/HCC incidence and survival over the
years to follow.
Antiretroviral risk factors of end-stage liver
disease and hepatocellular carcinoma
We identified cumulative use of ddI, d4T, TDF and APV
to be independently associated with an increased rate of
ESLD/HCC development, whereas use of FTC and
NVP were associated with decreased rates.
The association between cumulative ddI and d4Tuse and
excess ESLD/HCC incidence builds on the observations
of a number of relatively small studies of HIV-
monoinfected and viral hepatitis coinfected individuals
using various biomarkers of liver failure [5,14,18]. A
recent retrospective study among 146 HIV/HCV
coinfected persons found that each additional year of
use of these drugs was associated with a 50% increase in
the odds of progressing one or more grades on the Brunt
score [15]. Similarly, a subanalysis among 205 HIV/HCV
coinfected persons randomized to two types of anti-HCV
treatment found that ddI use was associated with three-
fold higher odds of histologically verified fibrosis [16],
and a European cross-sectional study of 671 HIV/HCV
coinfected persons found that a median use of ddI
exceeding 5 months increased the odds of severe liver
fibrosis by 70% [13].
The incidence rate of ESLD/HCC among those who had
been exposed to ddI and/or d4T was higher among
individuals who had discontinued the drugs, than among
those currently receiving them. This may reflect the fact
that those at highest underlying risk of ESLD/HCC may
be most likely to stop the d-drugs. Several mechanisms
have been suggested for d-drug hepatotoxicity including
inhibition of the mitochondrial DNA polymerase gamma
and the mitochondrial respiratory chain with resulting
oxidative damages and lactic acidosis [3,16,47,48], hepatic
steatosis (microvascular and macrovascular), hepatocel-
lular damage and ultimately development of cirrhosis
[13,15].
The observed higher incidence of ESLD/HCC did not
begin to decrease until 6 years after cessation of ddI and
d4T use, suggesting that exposure to the drugs may have
caused irreversible tissue damage. This finding is in
accordance with work from Scourfield et al. [34] who
found that the adverse liver effects of ddI developed late
and after use of the drug was discontinued. These
observations hence have important implications for the
clinical management of all HIV-positive persons with
current or prior d-drug use. Use of d-drugs should
therefore be avoided if possible, in particular in
individuals with high underlying risk of ESLD/HCC
such as those with viral hepatitis. Owing to the long-
lasting adverse effects of d-drugs also after their use have
been discontinued one might further consider intensify-
ing monitoring with liver biomarkers, and if abnormal,
by transient elastography or liver biopsy among individ-
uals with long-term prior d-drug use to better identify
individuals at increased ESLD/HCC risk.
In contrast to the associations seen with ddI and d4T, the
observed association between ESLD/HCC and TDF was
unexpected. As TDF may be used preferentially among
those with HBV coinfection, it may not be surprising that
we see an increased rate of hepatotoxicity in those
exposed to this drug [1,49]. Importantly, however, the
TDF association remained unchanged after stratifying
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Table 3. Associations between current, cumulative and past exposure to d-drugs (ddI and d4T) and rates of end-stage liver disease/
hepatocellular carcinoma (ESLD/HCC).
No other
factor
Adjusted for exposure to
other NRTIs, PIs and NNRTIs
Exposure to other NRTIs, PIs and
NNRTIs and potential confoundersc
Rate of ESLD/HCC
(per 1000 PYFUa, 95% CIa)
Relative rateb
(95% CI)
Relative rate
(95% CI)
Relative rate
(95% CI)
Never received d-drugs 0.50 (0.40, 0.61) 0.60 (0.37, 0.98) 0.65 (0.40, 1.05) 1.03 (0.60, 1.73)
Currently on d-drugs 1.30 (0.87, 1.76) Ref. Ref. Ref.
Stopped d-drugs and off for:
0, <2 years 1.89 (1.32, 2.45) 1.70 (1.07, 2.69) 1.72 (1.08, 2.72) 1.64 (1.03, 2.60)
2, <4 years 1.85 (1.30, 2.41) 1.60 (1.01, 2.52) 1.65 (1.04, 2.61) 1.59 (1.00, 2.52)
4, <6 years 1.93 (1.36, 2.50) 1.63 (1.04, 2.56) 1.72 (1.09, 2.73) 1.63 (1.03, 2.59)
6, <8 years 1.56 (1.00, 2.12) 1.34 (0.81, 2.20) 1.48 (0.89, 2.46) 1.48 (0.89, 2.47)
8 years 1.40 (0.95, 1.85) 1.25 (0.78, 2.01) 1.44 (0.88, 2.36) 1.49 (0.90, 2.47)
Cumulative exposure
(/year) to d-drugs
n/a 1.07 (1.03, 1.11) 1.07 (1.03, 1.12) 1.06 (1.01, 1.10)
aCI, confidence interval; d4T, stavudine; ddI, didanosine; NNRTIs, nonnucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse
transcriptase inhibitors; PIs, protease inhibitors; PYFU, person-years of follow-up.
bAdjusted for time since stopping d-drug and cumulative exposure to d-drug.
cAge, sex, injection drug use as mode of HIV acquisition, previous AIDS diagnosis, HBV, HCV, calendar period, time since stopping d-drug and
cumulative exposure to d-drugs.
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according to and adjusting for viral hepatitis status,
suggesting the association is not dependent on HBVand is
not simply explained by an increased ESLD/HCC risk
among individuals coinfected with HBV and preferen-
tially treated with TDF. Furthermore, a recent D:A:D
analysis which investigated predictors of chronic liver
enzyme elevation among individuals without viral
hepatitis also confirmed the positive association with
cumulative TDF use, supporting this observation [50].
Finally 3TC, which is also used to treat HBV infection,
although less often because of a lower genetic resistance
barrier, did not remain statistically significantly associated
with ESLD/HCC in adjusted models. Use of FTC,
which is commonly coprescribed with TDF (68% of
those currently on TDF were also on FTC) was further
independently associated with a lower ESLD/HCC risk
and further argues against the hypothesis that our
observed TDF association simply reflects a higher rate
of unreported HBV infection. Outside the D:A:D study,
only a few studies, predominantly smaller case reports,
have reported a positive association between liver
impairment and TDF [49,51,52]. This TDF association
does, however, seem to be robust in D:A:D and is related
to several liver outcomes, calling for confirmation in
other large studies. No biological mechanism is currently
known for TDF to cause ESLD/HCC, but the effect may
relate to the development of mitochondrial toxicity in
hepatocytes as described in renal tubular cells [53], and
steatosis is described in the TDF product information
[54]. Our results also call for further investigations in
mechanistic studies.
Based on the literature, if anything, one would have
expected use of NVP to be associated with increased risk
of ESLD/HCC [1,26,37–39]. Instead, we observed a
lower rate of ESLD/HCC associated with cumulative
NVP use. This may reflect the fact that NVP may only
contribute to acute, but not more advanced and chronic
stages of liver disease, but may also reflect some degree of
confounding by indication with NVP not being
prescribed to high-risk individuals, or being discontinued
in those who experience liver enzyme elevations after
starting the drug.
Elevated levels of transaminases are a common adverse
effect of APV, although a recent small study did not
identify a safety concern with long-term use [55,56]. A
recent mechanistic study further found some evidence to
support an anti-HCC effect of APV [57]. APV may,
because of its use in calculating dose recommendations for
various levels of liver impairment, preferably have been
used in individuals with liver impairment and the use is
currently limited [58]. No other statistically significant
associations were observed for cumulative use of other
protease inhibitors including ATV. This suggests that from
a clinical liver endpoint perspective, the commonly used
PIs can be safely used in HIV-positive individuals over
longer periods of time, a finding that is in accordance
with other recent studies using biomarker-defined
hepatotoxicity. Of note, use of TPV and darunavir are
still too limited to allow for robust statistical analyses in
D:A:D. Furthermore, our analysis did not consider any
impact of DAAs for treatment of HCV, where there are
known drug–drug interactions with PIs, as the use of
DAAs in D:A:D is still extremely low.
Limitations
The limitations of this analysis should be acknowledged
and include the lack of a systematic collection on
information on alcohol consumption. However, the
associations observed with use of ddI, d4T, TDF, APV,
NVP and FTC are unlikely to be confounded by alcohol
usage, as the choice of ART including these antiretrovirals
is unlikely to be modified by the clinician’s knowledge of
the individuals alcohol consumption. A high number of
antiretrovirals were included in the analysis, hence we
cannot rule out that findings may be a result of multiple
testing and the possibility of false-positive errors.
Confounding by indication cannot be ruled out for a
number of the included antiretrovirals, in particular, as
discussed, APV and NVP. Finally, nonantiretroviral
hepatotoxic treatment, such as antituberculosis treatment
with isoniazid and rifampicin, or sulphonamides used to
treat pneumocystis pneumoni, may represent unmeasured
confounding although adjustment for previous AIDS
events did not change any of the observed antiretroviral
associations.
Conclusion
While the ESLD/HCC incidence was relatively low in
this large heterogeneous cohort, and predominantly seen
in individuals with viral hepatitis coinfection, the
prognosis following a diagnosis was very poor. Cumu-
lative use of ddI, d4T, TDF and APV was independently
associated with increased rates of ESLD/HCC, whereas
use of NVP and FTC was associated with lower rates.
There was limited evidence for reversibility of ESLD/
HCC risk upon cessation of d-drugs, and intensified
monitoring of liver function and avoidance of hepato-
toxic compounds should hence be considered among all
with longer-term current or prior d-drug exposure. The
unexpected, and viral hepatitis independent, TDF
association calls for further investigations, whereas use
of d-drugs should be avoided, where there are alternatives
available.
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Pugliese, V. Rahelinirina, P.M. Roger. Clinical research
assistant: K. Dollet.
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Aubert, M. Battegay, E. Bernasconi, J. Bo¨ni, H.C.
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